IMUX — IMMUNIC, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1280776 ·
Last close
$7.33
Market Cap
$100.01M
52W High
$17.43
52W Low
$5.06
ADV30
300,713
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -43,369,000 | -42,309,000 | 136,423,000 | 131,963,000 | 31,950,000 |
| Jun 2026 | 0 | — | -35,327,000 | -34,099,000 | 159,169,000 | 155,098,000 | 31,588,000 |
| Mar 2026 | 0 | — | -33,235,000 | -32,588,000 | 189,742,000 | 186,629,000 | 38,509,000 |
| Dec 2025 | 0 | — | -23,327,000 | -19,300,000 | 24,052,000 | 15,483,000 | 30,725,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,720,000
Investing CF
$-329,000
Financing CF
$65,577,000
CapEx
$-329,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.18
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-675,258,000
Inventory
—
Receivables
$281,000
ST Investments
—
EBIT TTM
$-117,882,000
Pretax Income TTM
$-111,566,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,228,000 | -97,172,000 | 24,052,000 | 30,725,000 | -6,673,000 | -85,806,000 |
| Dec 2024 | 0 | -98,052,000 | -100,507,000 | 40,868,000 | 22,439,000 | 18,429,000 | -84,766,000 |
| Dec 2023 | 0 | -99,223,000 | -93,612,000 | 54,299,000 | 25,368,000 | 28,931,000 | -70,828,000 |
| Dec 2022 | 0 | -86,518,000 | -120,407,000 | 127,753,000 | 14,069,000 | 113,684,000 | -65,144,000 |
TTM Snapshot
Revenues TTM
$2,662,000
NetIncome TTM
$-111,566,000
OpCashFlow TTM
—
Assets (Latest)
$159,169,000
Forward EPS
$-2.37
Max Pain — expiry 2027-01-15
max pain strike: $7.50 · spot: $7.52 · call oi: 1,384 · put oi: 733
Expected Move to 2027-01-15:
±$4.10
(54.52%) —
implied range
$3.42 –
$11.62
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EQ | Equillium, Inc. | $99.61M | $1.21 | — |
| ADAG | Adagene Inc. | $99.37M | $1.48 | — |
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
| UNCY | Unicycive Therapeutics, Inc. | $101.35M | $3.70 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
News headlines (Yahoo Finance, 1h cache)
Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
2026-11-13 14:10 · Yahoo
Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results?
2026-11-13 13:47 · Yahoo
Immunic shares fall 5% on third quarter earnings miss
2026-11-13 12:14 · Yahoo
MARKETS LIVE: Wall Street ends volatile week mixed as Nvidia selloff weighs on tech stocks
2026-11-13 11:56 · Yahoo
Immunic: Q3 Earnings Snapshot
2026-11-13 11:36 · Yahoo
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 11:30 · Yahoo
Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts
2026-11-12 15:26 · Yahoo
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
2026-11-06 05:14 · Yahoo
Immunic to Participate in Investor Conferences in November
2026-11-02 11:30 · Yahoo
Immunic highlights progressive MS research and Phase 3 outlook at MSToronto2026
2026-10-30 17:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.